1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs
  4. >>Emerging Company Profiles

Early Data In Hand, Vesper Bio Takes On GSK And Alector

 
• By Elizabeth Cairns

Emerging Company Profile: Danish group Vesper Bio is advancing an oral sortilin inhibitor in frontotemporal dementia, and is aiming to get to market in a similar timeframe to its much larger rivals.    

Memory loss and brain aging due to dementia and alzheimer's disease as a medical icon of a group of color changing autumn fall trees shaped as a human head losing leaves on a white background.

While a handful of new Alzheimer’s drugs have made it to market in recent years, some groups are working on other forms of dementia. One such is Vesper Bio, whose sortilin inhibitor VES001 generated encouraging Phase I data in frontotemporal dementia earlier this month.

“We’ve shown that we have a safe and well tolerated drug … and we’ve shown that it gets into the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Emerging Company Profiles

Speedy FDA Review Could Save Stealth From Sinking

 
• By Kevin Grogan

The agency is expected to give its final verdict on elamipretide by the end of September.

Former Moderna Exec Launches Company Focused On mRNA Despite HHS Funding Cuts

 
• By David Wild

Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Immusoft Goes For Cell Therapy Plan ‘B’

 
• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

More from Leadership

Novartis Heralds Watershed Ianalumab Data In Sjogren’s

 
• By Kevin Grogan

The Swiss major plans to submit the positive results from the NEPTUNUS program to health authorities globally in early 2026.

Executives On The Move: Three New CEOs And Four New CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Climb Bio, Amphista Therapeutics and NRG Therapeutics, plus Novo Nordisk announces Board changes.

Outgoing Cipla CEO On Key Wins, Unfinished Agenda, Biosimilars ‘Explosion’ To Come

 
• By Anju Ghangurde

Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.